Compare Inovio Pharmaceuticals Inc (INO) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Southern Copper Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Southern Copper Corp trades at $182.78 (market cap $146.07B). The key difference: Southern Copper Corp is far larger — about 1636.3× Inovio Pharmaceuticals Inc's market cap, and Southern Copper Corp pays a 2.28% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SCCO | |
|---|---|---|
Market Cap | $89.27M | $146.07B |
Sector | Health | Basic Materials |
52-Week High | $2.87 | $218.85 |
52-Week Low | $1.05 | $90.54 |
Enterprise Value | $60.28M | $148.12B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Southern Copper (SCCO) trades at $175.27, up 1.62% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with revenue growth from $11.4B in 2024 to $13.4B in 2025 and net income rising to $4.3B. Valuation ratios are elevated with a P/E of 29.2 and P/B of 12.2. A recent dividend of $1.00 was declared, payable May 29, 2026, alongside a minor stock split.
Outlook is mixed: robust profitability and copper demand from AI infrastructure support growth, but high valuation and bearish analyst consensus pose risks. The consensus price target is $152.79, below the current price, indicating potential downside. Key risks include commodity price volatility and debt levels, though operational cash flow remains strong at $4.75B in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
